Dr. Casey is a consultant for Abbott, AstraZeneca, Janssen, Lilly, Novartis, and Pfizer; and is a member of the speakers/advisory board for Janssen, Lilly, and Pfizer.
Dr. Citrome has received speaker honoraria and/or consultant fees from Abbott, AstraZeneca, Janssen, Lilly, Novartis, and Pfizer, as well as research support/contracts from Abbott, Bristol-Myers-Squibb, Janssen, and Novartis.
Dr. Daniel is a consultant and a member of the speakers/advisory board for Abbott, Pfizer, Bristol-Myers, Otsuka, Janssen, PRI; has received research grant support from Abbott, Pfizer, Bristol-Myers, Otsuka, Janssen, PRI, Lilly, AstraZeneca, and Sumiton.
Dr. Swann is a consultant for Abbott, Glaxo, Novartis, and Shire; is a member of the speakers or advisory boards for Abbott, Glaxo, Novartis, and Janssen; and has received honoraria or grant/research support from Abbott, Glaxo, Janssen, Novartis, Shire, Bristol-Myers-Squibb, and Robert Wood Johnson.
Dr. Tariot is a consultant for Lilly, AstraZeneca, Pfizer, Abbott, Bristol-Myers, Novartis, and Janssen; and is a member of the speakers/advisory board for Janssen, Pfizer, AstraZeneca, Abbott, Lilly, and Novartis.
Dr. Spencer has received grant/research support from, is a member of the speaker's bureau for, and is a consultant for McNeil, Alza, Celltech Medieva, GlaxoSmithKline, Lilly, National Institute of Mental Health, Novartis, Pfizer, and Shire.
Dr. Adler is a consultant for Celgene, Novartis, Lilly, Ortho-McNeil, and Shire; has received grant/research support from Celgene, Lilly, Pfizer, Novartis, and GlaxoSmithKline; and has received honoraria from GlaxoSmithKline, Lilly, Ortho-McNeil, Pfizer, and Novartis.
Dr. Barkley has received royalties from Guilford Press.
Dr. Kratochvil is a consultant for Lilly, Shire and Alza; has received grant/research support from Lilly, McNeil, and GlaxoSmithKline; has received honoraria from Lilly, and is on the speakers/advisory boards for Lilly and Novartis.
Dr. Saylor is a consultant for Lilly and has received honoraria from Physicians Postgraduate Press, Inc.
Dr. Wernicke is an employee of Lilly.
Dr. Buermeyer has no financial or other relationships with any organization or entity to disclose.
Dr. Casey
is a consultant for Abbott, AstraZeneca, Aventis,
Bristol-Myers Squibb, Janssen, Eli Lilly, Novartis, and Pfizer;
and is on the speakers or advisory boards for Abbott,
Bristol-Myers Squibb, Janssen, Eli Lilly,
and Pfizer.
Dr. Citrome is a consultant for Eli Lilly and Abbott; has received research/grant support from Janssen, Abbott, Bristol-Myers Squibb, and Eli Lilly; has received honoraria from and is a member of the speakers or advisory boards for Abbott, Bristol-Myers Squibb, AstraZeneca, Novartis, Eli Lilly, and Pfizer.
Dr. Daniel is a consultant for, has received honoraria from, and is a member of the speakers or advisory boards for Abbott, Pfizer, Bristol-Myers Squibb, Otsuka, and Sumitomo.
Dr. Nasrallah is a consultant for, has received honoraria from, and is a member of the speakers or advisory boards for Abbott, AstraZeneca, Bristol-Myers Squibb, Janssen, and Pfizer; and has received grant/research support from AstraZeneca, Janssen, and Pfizer.
Dr. Stahl is a consultant for and has received honoraria from Asahi-Kasei, Abbott, AstraZeneca, Aventis, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Cypress Bioscience, Eli Lilly, Pierre Fabre, Forest, GlaxoSmithKline, Janssen, Lorex, Lundbeck, Neurocrine, Novartis, Organon, Parke-Davis, Pfizer, Pharmacia, Roche, Sanao, Sanofi-Synthelabo, Searle, Solvay, Sumitomo, Takeda, Watson, Wyeth, and Yamanouchi; has received grant/research support from Asahi-Kasei, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Cypress Bioscience, Pierre Fabre, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Lundbeck, Organon, Parke-Davis, Pfizer, Pharmacia, Sanofi-Synthelabo, Solvay, Watson, Wyeth, and Yamanouchi; and is a member of the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Lundbeck, Organon, Parke-Davis, Pfizer, Pharmacia, Sanofi-Synthelabo, Solvay, Watson, and Wyeth.
Dr. Biederman receives research support from Shire Richwood, Eli Lilly, Wyeth, Pfizer, Cephalon, Janssen, Noven, Stanley Foundation, National Institute for Mental Health, National Institute of Child Health and Human Development, and National Institute on Drug Abuse; is a member of the speakers' bureaus of GlaxoSmithKline, Eli Lilly, Pfizer, Wyeth, Shire Richwood, Alza, and Cephalon; and is a member of the advisory boards of Eli Lilly, Celltech, Shire Richwood, Noven, Alza, Ortho-McNeil, and Cephalon.
Dr. Kratochvil is a consultant for and has received honoraria from Eli Lilly; has received research and/or grant support from Eli Lilly, Ortho-McNeil, and GlaxoSmithKline; and is a member of the speakers' and/or advisory boards of Eli Lilly, Shire Richwood, and Novartis.
Dr. Spencer has received research and/or grant support, is a consultant for, and/or is a member of the speakers' bureaus of Abbott, Boston Life Sciences, Bristol-Myers Squibb, Cephalon, Celltech, Eisai, Eli Lilly, GlaxoSmithKline, Novartis, Ortho-McNeil, Pfizer, Shire Richwood, and Wyeth.
Dr. Wozniak has received research and/or grant support from and is a major stock shareholder of Eli Lilly and has received honoraria from and is a member of the speakers' and/or advisory boards of Eli Lilly and Janssen.
Dr. Marder is a consultant for Janssen, Eli Lilly, Novartis, AstraZeneca, and Bristol-Myers; has received grant/research support from Janssen, Eli Lilly, AstraZeneca, and Bristol-Myers; has received honoraria from Janssen, Eli Lilly, Bristol-Myers, and Pfizer; and is a member of the speakers/advisory board for Janssen, Eli Lilly, and Bristol-Myers.
Dr. Ereshefsky is a consultant for and has received grant/research support and honoraria from Janssen, Eli Lilly, AstraZeneca, and Pfizer; is a member of the speakers/advisory board for Pfizer, Janssen, and Eli Lilly; and is a major stock shareholder with Pfizer and Johnson & Johnson.
Dr. Fleischhacker is a consultant for, has received grant/research support from, and is a member of the speakers/advisory board for Janssen.
Dr. Kane is a consultant for Janssen, Pfizer, Abbott, Novartis, and AstraZeneca; has received grant/research support from Pfizer, Novartis, and Eli Lilly; has received honoraria from Eli Lilly; and is a member of the speakers/advisory board for Lundbeck.
Dr. Schooler has received grant/research support from Novartis, Bristol-Myers, and Pfizer; has received honoraria from Janssen, Pfizer, and Eli Lilly; and is a member of the speakers/advisory board for Janssen, Pfizer, and Bristol-Myers.
Dr. Davis has no significant commercial relationships to disclose relative to his presentation.
Dr. Jain is a consultant for Eli Lilly and GlaxoSmithKline; has received grant/research support from Wyeth, GlaxoSmithKline, Eli Lilly, and Merck; has received honoraria from Wyeth, GlaxoSmithKline, and Eli Lilly; and is a member of the speakers/advisory board for Eli Lilly.
Dr. Duesenberg is a consultant for and has received honoraria from Eli Lilly and Shire Richwood; has received grant/research support from Eli Lilly, Shire Richwood, Novartis, and Johnson & Johnson; and is a member of the speakers/advisory boards for Eli Lilly, Shire Richwood, and Forest.
Dr. Donnelly is an employee of Dartmouth Medical School; is a consultant for Eli Lilly and Pfizer; has received grant/research support from Janssen, Pfizer, and Eli Lilly; has received honoraria from GlaxoSmithKline and AstraZeneca; and is a member of the speakers/advisory boards for Eli Lilly, Pfizer, Janssen, and GlaxoSmithKline.
Dr. Biederman has received research support from Shire Richwood, Eli Lilly, Wyeth, Pfizer, Cephalon, Novartis, Janssen, Noven Pharmaceutical, Stanley Foundation, the National Institute of Mental Health (NIMH), the National Institute of Child Health & Human Development, and the National Institute on Drug Abuse (NIDA); is a member of the speakers bureaus for GlaxoSmithKline, Eli Lilly, Pfizer, Novartis, Wyeth, Shire Richwood, ALZA, and Cephalon; and is a member of the advisory boards for Eli Lilly, Celltech, Shire Richwood, Novartis, Noven Pharmaceutical, ALZA, McNeil, and Cephalon.
Dr. Adler is a consultant for, has received grant/research support and honoraria from, and is a member of the speakers or advisory boards for Novartis, Abbott, Eli Lilly, Pfizer, Merck, McNeil, and Johnson & Johnson.
Dr. Montano is a consultant for Eli Lilly, GlaxoSmithKline, Organon, Forest, Roche, and Wyeth; has received grant/research support from Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline; and has received honoraria from and is a member of the speakers or advisory boards for Eli Lilly, GlaxoSmithKline, Forest, Organon, and Wyeth.
Dr. Spencer has received research support from Abbott, Bristol-Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Janssen, McNeil, Celltech, Novartis, Pfizer, Shire Richwood, and Wyeth; is a member of the speakers bureaus of Eli Lilly, GlaxoSmithKline, Janssen, McNeil, Celltech, Novartis, Shire Richwood, and Wyeth; and is a consultant for Eli Lilly, GlaxoSmithKline, Janssen, McNeil, Novartis, Pfizer, and Shire Richwood.
Dr. Weiss has received grant/research support from Circa Dia and Eli Lilly and is a consultant for, has received honoraria from, and is a member of the speakers or advisory boards of Eli Lilly, GlaxoSmithKline, Circa Dia, Shire Richwood, Novartis, Purdue Pharma, and Janssen.
Dr. Wilens is a consultant for, has received grant/research support from, and is a member of the speakers bureaus of Abbott, Celltech, Eli Lilly, McNeil, NIDA, NIMH, Novartis, Pfizer, Shire Richwood, and GlaxoSmithKline.
Dr. Murphy has no financial relationships to disclose significant to the presentation.
Dr. Nemeroff has received grant/research support from Abbott, American Foundation for Suicide Prevention, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Merck, National Alliance for Research on Schizophrenia and Depression, National Institute of Mental Health, Pfizer, Stanley Foundation/NAMI, and Wyeth; is a consultant for Abbott, Acadia Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Corcept, Cypress Bioscience, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Neurocrine Biosciences, Novartis, NPS Pharmaceuticals, Organon, Otsuka, Sanofi-Synthelabo, Scirex, Somerset, and Wyeth; is a member of the speakers bureaus for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Organon, Otsuka, Pfizer, and Wyeth; is a stockholder for Corcept and Neurocrine Biosciences; is on the boards of directors for American Foundation for Suicide Prevention, Cypress Bioscience, George West Mental Health Foundation, Novadel Pharma, and Heinz C. Prechter Fund for Manic Depression; and holds patents on method and devices for transdermal delivery of lithium (US 6,375,990 B1), and method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing, April 2001).
Dr. Blier has received grant/research support Janssen, Eli Lilly, and Forest; is on the speakers/advisory boards for Janssen, Eli Lilly, Forest, and Lundbeck; and has presented expert testimony for Eli Lilly.
Dr. Keller is a consultant for and has received honoraria from Bristol-Myers Squibb, Collegium, Cypress Bioscience, Cyberonics, Eli Lilly, Forest, Janssen, Merck, Organon, Otsuka, Pfizer, Pharmacia, Pharmastar, Seprecor, Vela, and Wyeth; has received grant/research support from Eli Lilly, Forest, Merck, Organon, Pfizer, and Wyeth; and is a member of the advisory boards for Abbott, Bristol-Myers Squibb, Cephalon, Cyberonics, Cypress Bioscience, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Merck, Mitsubishi Pharma, Novartis, Organon, Pfizer, Pharmacia, Sanofi-Synthelabo, Scirex, Sepracor, Somerset, Vela, and Wyeth.
Dr. Pollack is on the advisory boards for Bristol-Myers Squibb, Cephalon, Forest, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Otsuka, Pfizer, Roche, UCB Pharma, and Wyeth; has received grant/research support from Cephalon, Forest, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, UCB Pharma, and Wyeth; and is involved with speaker programs for Forest, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, Solvay, and Wyeth.
Dr. Charney has no affiliations or other relationships to disclose relevant to the presentation.
Dr. Baron is a consultant for AstraZeneca and Eli Lilly; has received grant/research support from Pfizer, Eli Lilly, Janssen, and Johnson & Johnson; has received honoraria from Janssen, Eli Lilly, and AstraZeneca; and is a member of the speakers/advisory boards of Janssen, Pfizer, Eli Lilly, and AstraZeneca.
Dr. Menza has received grant/research support from National Institutes of Health, Pfizer, Merck, AstraZeneca, Wyeth, Cephalon, Eli Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Forest, Pharmacia, Novartis, Hoechst Marion Roussel, and Bayer; has received honoraria from Pfizer, AstraZeneca, Wyeth, Cephalon, Eli Lilly, Bristol-Myers Squibb, and Pharmacia; and is a consultant for Pfizer, Cephalon, Eli Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Forest, Hoechst Marion Roussel, and Bayer.
Dr. Wise is a consultant for Eli Lilly, Bristol-Myers Squibb, Pfizer, and Ortho-McNeil; and is a member of the speakers/advisory boards of Eli Lilly, Bristol-Myers Squibb, and Pfizer.